13-32340561-T-G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000059.4(BRCA2):c.6206T>G(p.Leu2069*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000059.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.6206T>G | p.Leu2069* | stop_gained | Exon 11 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.5837T>G | p.Leu1946* | stop_gained | Exon 11 of 27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.6206T>G | non_coding_transcript_exon_variant | Exon 10 of 26 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 46
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:6
- -
This variant changes 1 nucleotide in exon 11 of the BRCA2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in an individual affected with breast cancer (PMID: 16912212), one unaffected individual (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA2_004908) and in four families among the CIMBA participants (PMID: 29446198). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
- -
Variant allele predicted to encode a truncated non-functional protein. -
- -
The c.6206T>G (p.Leu2069*) variant in the BRCA2 gene is predicted to introduce a premature translation termination codon, which is predicted to result in nonsense-mediated mRNA decay. This variant is absent from large databases of genetic variation in the general population. This variant has been reported in one patient with breast cancer (PMID 16912212). Another variant in the BRCA2 gene, c.6206delT, predicting to result in the same p.Leu2069* amino acid change, has been reported in a family affected with breast and ovarian cancer (PMID 9150172). Therefore, the c.6206T>G (p.Leu2069*) variant in the BRCA2 gene is classified as pathogenic. -
Hereditary breast ovarian cancer syndrome Pathogenic:4
This sequence change creates a premature translational stop signal (p.Leu2069*) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 38026). For these reasons, this variant has been classified as Pathogenic. -
Variant summary: BRCA2 c.6206T>G (p.Leu2069*) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 250212 control chromosomes. c.6206T>G has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (e.g., Petridis_2019, Rebbeck_2018). These data indicate that the variant may be associated with disease. Additionally, the same p.Leu2069* amino acid change caused by a different variant (c.6206delT) has been reported as pathogenic in ClinVar. The following publications have been ascertained in the context of this evaluation (PMID: 31060593, 29446198). ClinVar contains an entry for this variant (Variation ID: 38026). Based on the evidence outlined above, the variant was classified as pathogenic. -
The p.Leu2069X variant in BRCA2 has been reported in at least 3 individuals with BRCA2-associated cancers (Breast Cancer Information Core (BIC) database and Sharing Clinical Reports Project). It was also absent from large population studies. This nonsense variant leads to a premature termination codon at position 2069, which is predicted to lead to a truncated or absent protein. Heterozygous loss of function of the BRCA2 gene is an established disease mechanism in hereditary breast and ovarian cancer (HBOC). In addition, this variant was classified as Pathogenic on September 8, 2016 by the ClinGen-approved ENIGMA expert panel (ClinVar SCV000300999). In summary, this variant meets criteria to be classified as pathogenic for HBOC in an autosomal dominant manner. ACMG/AMP criteria applied: PVS1, PM2, PS4_Supporting. -
- -
not provided Pathogenic:3
Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Malone 2006, Rebbeck 2018); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at a significant frequency in large population cohorts (gnomAD); Also known as 6434T>G; This variant is associated with the following publications: (PMID: 16912212, 9150172, 29446198, 31447099, 30787465) -
The BRCA2 p.Leu2069* variant was identified in a multicenter (consortia) study by CIMBA in 2 of 22702 proband chromosomes (frequency: 0.00009) from females with BRCA2 pathogenic variants, the affected individuals being Caucasian American (Rebbeck 2018). The variant was also identified in dbSNP (ID: rs80358859) as “With Pathogenic allele”, in ClinVar (classified pathogenic, reviewed by an expert panel (2016); submitters: GeneDx, Invitae, Ambry Genetics, ENIGMA, CIMBA, and 3 other laboratories), and LOVD 3.0 (1x as pathogenic). The variant was not identified in the UMD-LSDB database. The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The c.6206T>G variant leads to a premature stop codon at position 2069 which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in hereditary breast and ovarian cancer and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. -
The BRCA2 c.6206T>G (p.Leu2069*) variant causes the premature termination of BRCA2 protein synthesis. In the published literature, this variant has been reported in an individual with breast cancer (PMID: 16912212 (2006)), and observed in a world-wide screening study of families with BRCA1 and BRCA2 pathogenic variants (PMID: 29446198 (2018)). The same p.Leu2069* amino acid change caused by a different variant (c.6206del) has also been reported in a family with breast and/or ovarian cancer (PMID: 9150172 (1997)). The c.6206T>G (p.Leu2069*) variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:2
The p.L2069* pathogenic mutation (also known as c.6206T>G), located in coding exon 10 of the BRCA2 gene, results from a T to G substitution at nucleotide position 6206. This changes the amino acid from a leucine to a stop codon within coding exon 10. A single nucleotide deletion resulting in a stop codon at the same position (p.L2069*) has been identified in a French family with female breast and ovarian cancer (Serova-Sinilnikova OM et al. Am. J. Hum. Genet. 1997 May; 60(5):1236-9). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
- -
Familial cancer of breast Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at